植物疗法采用源自植物的植物成分/植物药物来治疗和预防疾病。睡茄因其药用用途和药理特性而被印度阿育吠陀药典所熟知。在本研究中，我们检测了睡茄茎甲醇提取物 (WSME) 的生物活性谱，该物质因其广泛的药用用途而被视为“Rasayana”。对 WSME 进行了 TPC 和 TFC 定量，并对生物活性成分进行了定量分析。使用 LC-MS 进行表征。通过 DPPH 和 H2O2 自由基清除测定来衡量其抗氧化潜力，同时使用纸片扩散测定来评估对金黄色葡萄球菌和大肠杆菌的抗菌功效。针对人乳腺癌 MDA-MB-231 细胞评估了体外抗癌活性，并使用 MTT 法评估了针对正常 Vero 细胞的毒性。富含 Withaferin A 的 WSME 的 TPC 为 4.73 ± 0.15 mg GAE/g，TFC 为 94.94 ± 6.15mg QE/g 提取物干重。它表现出显着的抗氧化活性（使用 DPPH 和 H2O2 测定，在 1,000μg/mL 下分别抑制 43.28% 和 66.8%），并对金黄色葡萄球菌（300-500mg/mL）具有轻微的抗菌作用。 WSME 诱导 MDA-MB-231 细胞死亡，并显着抑制其生长（IC50：66μg/mL，P 值<0.05），在 25-400 μg/mL 的研究范围内（IC50：6.09 mg）不影响正常 Vero 细胞。 /mL, P 值>0.05)。本研究为进一步测试 WSME 针对其他癌细胞系和癌症动物模型提供了支持。这些临床前研究将进一步验证其作为人类乳腺癌治疗辅助手段的预期用途。© 2024 Walter de Gruyter GmbH，柏林/波士顿。

Phytotherapy employs phytoconstituents/phytomedicines derived from plants for treating and preventing illnesses. Withania somnifera is known in the Indian Ayurveda Pharmacopoeia for its medicinal applications and pharmacological properties. In this study, we examined the biological activity spectrum of Withania somnifera methanolic extract of stem (WSME), which is valued as a "Rasayana" due to its extensive range of medicinal uses.WSME was subjected to TPC and TFC quantification and bioactive components were characterized using LC-MS. Its antioxidant potential was gauged by DPPH and H2O2 radical scavenging assays, while antibacterial efficacy was assessed against S. aureus and E. coli using disc diffusion assay. In vitro anticancer activity was evaluated against human breast cancer MDA-MB-231 cells while toxicity was evaluated against normal Vero cells using MTT assay.WSME, rich in Withaferin A, showed TPC of 4.73 ± 0.15 mg GAE/g and TFC of 94.94 ± 6.15 mg QE/g dry weight of extract. It exhibited significant antioxidant activity (43.28 and 66.8 % inhibition at 1,000 μg/mL using DPPH and H2O2 assays, respectively) and mild antibacterial effects against S. aureus (300-500 mg/mL). WSME induced cell death in MDA-MB-231 cells and significantly inhibited their growth (IC50: 66 μg/mL, P value<0.05) without affecting normal Vero cells in the studied range of 25-400 μg/mL (IC50: 6.09 mg/mL, P value>0.05).The present study lends support to further testing of WSME against other cancer cell lines and animal models of cancer. These preclinical studies would provide further validation to its prospective use as an adjunct in human breast cancer therapy.© 2024 Walter de Gruyter GmbH, Berlin/Boston.